Haroutyun Joulfayan

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 7

Top Topics

Drug Administration

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Authors' Response to Peer Reviews of "Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis". JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis. JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis. JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Authors' Response to Peer Reviews of "Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis". JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis. JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis. JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Authors' Response to Peer Reviews of "Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis". JMIRx med 5 (2024)